Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 29, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On January 26, 2007, this re-valuation resulted in an increase in the notional allocation of Ordinary Share ADRs for several individuals at a price of $54.61 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on January 26, 2007.
- Share Price: The transaction price was $54.61 per share.
- Participants: The notification covers nine individuals, including Dr. J P Garnier (91 shares), Mr. D Stout (43 shares), and Mr. D Phelan (21 shares), among others.
- Plan Type: The transaction relates to the US Retirement Savings Plan held in GSK Ordinary Share ADRs.